- Building Value into Reimbursement for Prescription Digital Therapeutics
- Enabling Clinical Trial Innovation Through AI Regulation at FDA
- Prioritizing Patient Care: Medical Technology Innovations on the Horizon
- Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
- Where Do We Go from Here on Digital Therapeutics?
- Updates in Federal Legislation Addressing Digital Therapeutics, Access to Care
- FDA Forms New Digital Health Advisory Committee to Cover Growing Role of Tech
- Researchers Developing Mixed Reality Naloxone Training to Combat Opioid Overdose Deaths
- FDA Clears Prescription Digital Behavioral Therapeutic for Type 2 Diabetes